Moving molecular targeted drug therapy towards personalized medicine: Issues related to clinical trial design

Por Verweij, Jaap, de Jonge, Maja, Eskens, Ferry, Sleijfer, Stefan
Publicado no Mol Oncol (2012)

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Por Hamberg, Paul, Woo, Margaret M., Chen, Lin-Chi, Verweij, Jaap, Porro, Maria Grazia, Zhao, Lily, Li, Wenkui, van der Biessen, Diane, Sharma, Sunil, Hengelage, Thomas, de Jonge, Maja
Publicado em 2011

The c-Met tyrosine kinase inhibitor JNJ-38877605 causes renal toxicity through species specific insoluble metabolite formation

Por Lolkema, Martijn P., Bohets, Hilde H., Arkenau, Hendrik-Tobias, Lampo, Ann, Barale, Erio, de Jonge, Maja J.A., van Doorn, Leni, Hellemans, Peter, de Bono, Johann S., Eskens, Ferry A.L.M.
Publicado no Clin Cancer Res (2015)

A phase I pharmacokinetic and safety study of cabazitaxel in adult cancer patients with normal and impaired renal function

Por Azaro, Analía, Rodón, Jordi, Machiels, Jean-Pascal, Rottey, Sylvie, Damian, Silvia, Baird, Richard, Garcia-Corbacho, Javier, Mathijssen, Ron H. J., Clot, Pierre-François, Wack, Claudine, Shen, Liji, de Jonge, Maja J. A.
Publicado no Cancer Chemother Pharmacol (2016)

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

Por de Weger, Vincent A., de Jonge, Maja, Langenberg, Marlies H. G., Schellens, Jan H. M., Lolkema, Martijn, Varga, Andrea, Demers, Brigitte, Thomas, Koruth, Hsu, Karl, Tuffal, Gilles, Goodstal, Samantha, Macé, Sandrine, Deutsch, Eric
Publicado no Br J Cancer (2018)

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib

Por Steeghs, Neeltje, Mathijssen, Ron H. J., Wessels, Judith A. M., de Graan, Anne-Joy, van der Straaten, Tahar, Mariani, Mariangela, Laffranchi, Bernard, Comis, Silvia, de Jonge, Maja J. A., Gelderblom, Hans, Guchelaar, Henk-Jan
Publicado em 2010

Evaluation of Patient Enrollment in Oncology Phase I Clinical Trials

Por van der Biessen, Diane A.J., Cranendonk, Merlijn A., Schiavon, Gaia, van der Holt, Bronno, Wiemer, Erik A.C., Eskens, Ferry A.L.M., Verweij, Jaap, de Jonge, Maja J.A., Mathijssen, Ron H.J.
Publicado em 2013

TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma

Por Jung, Joonil, Lee, Joon Sang, Dickson, Mark A., Schwartz, Gary K., Le Cesne, Axel, Varga, Andrea, Bahleda, Rastilav, Wagner, Andrew J., Choy, Edwin, de Jonge, Maja J., Light, Madelyn, Rowley, Steve, Macé, Sandrine, Watters, James
Publicado no Nat Commun (2016)

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520

Por Verheijen, Remy B., van der Biessen, Diane A. J., Hotte, Sebastien J., Siu, Lillian L., Spreafico, Anna, de Jonge, Maja J. A., Pronk, Linda C., De Vos, Filip Y. F. L., Schnell, David, Hirte, Hal W., Steeghs, Neeltje, Lolkema, Martijn P.
Publicado no Target Oncol (2019)

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Por van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.
Publicado no Br J Cancer (2020)

Realizing better doctor-patient dialogue about choices in palliative care and early phase clinical trial participation: towards an online value clarification tool (OnVaCT)

Por van Lent, Liza G. G., Stoel, Nicole K., van Weert, Julia C. M., van Gurp, Jelle, de Jonge, Maja J. A., Lolkema, Martijn P., Gort, Eelke H., Pulleman, Saskia M., Oomen-de Hoop, Esther, Hasselaar, Jeroen, van der Rijt, Carin C. D.
Publicado no BMC Palliat Care (2019)

Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies

Por de Jonge, Maja J. A., Steeghs, Neeltje, Lolkema, Martijn P., Hotte, Sebastien J., Hirte, Hal W., van der Biessen, Diane A. J., Abdul Razak, Albiruni R., De Vos, Filip Y. F. L., Verheijen, Remy B., Schnell, David, Pronk, Linda C., Jansen, Monique, Siu, Lillian L.
Publicado no Target Oncol (2019)

CMET-22. CAPMATINIB (INC280) IN METΔEX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY

Por Heist, Rebecca S, Seto, Takashi, Han, Ji-Youn, Reguart, Noemi, Garon, Edward B, Groen, Harry J M, Tan, Daniel S W, Hida, Toyoaki, de Jonge, Maja, V Orlov, Sergey, Smit, Egbert F, Souquet, Pierre-Jean, Vansteenkiste, Johan, Le Mouhaer, Sylvie, Robeva, Anna, Waldron-Lynch, Maeve, Giovannini, Monica, Wolf, Juergen
Publicado no Neuro Oncol (2019)

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Por van der Biessen, Diane A. J., Gietema, Jourik A., de Jonge, Maja J. A., Desar, Ingrid M. E., den Hollander, Martha W., Dudley, Matthew, Dunbar, Martin, Hetman, Robert, Serpenti, Camille, Xiong, Hao, Mittapalli, Rajendar K., Timms, Kirsten M., Ansell, Peter, Ratajczak, Christine K., Shepherd, Stacie Peacock, van Herpen, Carla M. L.
Publicado no Invest New Drugs (2018)

Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded...

Por de Leng, Wendy W. J., Gadellaa-van Hooijdonk, Christa G., Barendregt-Smouter, Françoise A. S., Koudijs, Marco J., Nijman, Ies, Hinrichs, John W. J., Cuppen, Edwin, van Lieshout, Stef, Loberg, Robert D., de Jonge, Maja, Voest, Emile E., de Weger, Roel A., Steeghs, Neeltje, Langenberg, Marlies H. G., Sleijfer, Stefan, Willems, Stefan M., Lolkema, Martijn P.
Publicado no PLoS One (2016)

Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study

Por Weeber, Fleur, Cirkel, Geert A., Hoogstraat, Marlous, Bins, Sander, Gadellaa-van Hooijdonk, Christa G.M., Ooft, Salo, van Werkhoven, Erik, Willems, Stefan M., van Stralen, Marijn, Veldhuis, Wouter B., Besselink, Nicolle J.M., Horlings, Hugo M., Steeghs, Neeltje, de Jonge, Maja J., Langenberg, Marlies H.G., Wessels, Lodewyk F.A., Cuppen, Edwin P.J.G., Schellens, J.H., Sleijfer, Stefan, Lolkema, Martijn P., Voest, Emile E.
Publicado no Oncotarget (2017)

53BP1 as a Potential Predictor of Response in PARP Inhibitor-Treated Homologous Recombination-Deficient Ovarian Cancer

Por Hurley, Rachel M., Hendrickson, Andrea E. Wahner, Visscher, Daniel W., Ansell, Peter, Harrell, Maria I., Wagner, Jill M., Negron, Vivian, Goergen, Krista M., Maurer, Matthew J., Oberg, Ann L., Meng, X. Wei, Flatten, Karen S., De Jonge, Maja J. A., Van Herpen, Carla D., Gietema, Jourik A., Koornstra, Rutger H.T., Jager, Agnes, den Hollander, Martha W., Dudley, Matthew, Shepherd, Stacie P., Swisher, Elizabeth M., Kaufmann, Scott H.
Publicado no Gynecol Oncol (2019)

Implementation of a Multicenter Biobanking Collaboration for Next‐Generation Sequencing‐Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies

Por Bins, Sander, Cirkel, Geert A., Gadellaa‐Van Hooijdonk, Christa G., Weeber, Fleur, Numan, Isaac J., Bruggink, Annette H., van Diest, Paul J., Willems, Stefan M., Veldhuis, Wouter B., van den Heuvel, Michel M., de Knegt, Rob J., Koudijs, Marco J., van Werkhoven, Erik, Mathijssen, Ron H.J., Cuppen, Edwin, Sleijfer, Stefan, Schellens, Jan H.M., Voest, Emile E., Langenberg, Marlies H.G., de Jonge, Maja J.A., Steeghs, Neeltje, Lolkema, Martijn P.
Publicado no Oncologist (2016)